Redcare Pharmacy NV (RDC.DE)
EUR 126.5
(1.28%)
EUR 126.5
(1.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 191.33 Million EUR | 1.37% |
| 2022 | 188.75 Million EUR | 1879.35% |
| 2021 | -10.6 Million EUR | 79.55% |
| 2020 | -51.88 Million EUR | -159.95% |
| 2019 | 86.54 Million EUR | 34.46% |
| 2018 | 64.36 Million EUR | 1173.23% |
| 2017 | -5.99 Million EUR | 84.06% |
| 2016 | -37.61 Million EUR | -343.12% |
| 2015 | 15.47 Million EUR | 5309.76% |
| 2014 | -297 Thousand EUR | -222.83% |
| 2013 | -92 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 164.98 Million EUR | 14.0% |
| 2024 Q1 | 144.73 Million EUR | -24.35% |
| 2023 Q1 | 158.93 Million EUR | -15.8% |
| 2023 Q2 | 126.51 Million EUR | -20.4% |
| 2023 Q4 | 191.33 Million EUR | 106.55% |
| 2023 FY | 191.33 Million EUR | 1.37% |
| 2023 Q3 | 92.63 Million EUR | -26.78% |
| 2022 Q4 | 188.75 Million EUR | 18.36% |
| 2022 Q1 | -18.68 Million EUR | -76.18% |
| 2022 Q2 | 42.26 Million EUR | 326.12% |
| 2022 FY | 188.75 Million EUR | 1879.35% |
| 2022 Q3 | 159.48 Million EUR | 277.38% |
| 2021 Q4 | -10.6 Million EUR | 57.06% |
| 2021 Q3 | -24.7 Million EUR | 29.21% |
| 2021 Q2 | -34.9 Million EUR | 26.27% |
| 2021 Q1 | -47.33 Million EUR | 8.76% |
| 2021 FY | -10.6 Million EUR | 79.55% |
| 2020 FY | -51.88 Million EUR | -159.95% |
| 2020 Q4 | -51.88 Million EUR | -196.98% |
| 2020 Q3 | 53.49 Million EUR | -1.24% |
| 2020 Q2 | 54.16 Million EUR | -50.68% |
| 2020 Q1 | 109.83 Million EUR | 26.91% |
| 2019 Q3 | -70.22 Million EUR | 18.79% |
| 2019 Q4 | 86.54 Million EUR | 223.25% |
| 2019 FY | 86.54 Million EUR | 34.46% |
| 2019 Q1 | 71.64 Million EUR | 11.3% |
| 2019 Q2 | -86.46 Million EUR | -220.7% |
| 2018 Q1 | -17.99 Million EUR | -200.08% |
| 2018 FY | 64.36 Million EUR | 1173.23% |
| 2018 Q4 | 64.36 Million EUR | 260.09% |
| 2018 Q3 | -40.2 Million EUR | 23.88% |
| 2018 Q2 | -52.82 Million EUR | -193.49% |
| 2017 Q3 | -30.46 Million EUR | -3.24% |
| 2017 Q2 | -29.5 Million EUR | 15.48% |
| 2017 Q4 | -5.99 Million EUR | 80.31% |
| 2017 FY | -5.99 Million EUR | 84.06% |
| 2017 Q1 | -34.91 Million EUR | 7.19% |
| 2016 Q2 | 9.25 Million EUR | 162.31% |
| 2016 Q1 | 3.52 Million EUR | -77.19% |
| 2016 FY | -37.61 Million EUR | -343.12% |
| 2016 Q4 | -37.61 Million EUR | -372.59% |
| 2016 Q3 | 13.8 Million EUR | 49.08% |
| 2015 Q1 | 297 Thousand EUR | 0.0% |
| 2015 Q4 | 15.47 Million EUR | 0.0% |
| 2015 FY | 15.47 Million EUR | 5309.76% |
| 2014 FY | -297 Thousand EUR | -222.83% |
| 2013 FY | -92 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Newron Pharmaceuticals S.p.A. | 42.09 Million EUR | -354.496% |